Compare DexCom, Inc. (DXCM) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Western Alliance Bancorporation — how do they compare? DexCom, Inc. trades at $77.6 (market cap $28.06B), while Western Alliance Bancorporation trades at $84.33 (market cap $8.93B). The key difference: DexCom, Inc. is far larger — about 3.1× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.05% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | WAL | |
|---|---|---|
Market Cap | $28.06B | $8.93B |
Sector | Health | Financials |
52-Week High | $89.53 | $96.08 |
52-Week Low | $54.84 | $66.70 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Western Alliance Bancorporation (WAL) trades at $83.33, up 3.7% on the day, with a bullish technical signal from moving averages and strong analyst consensus. The stock shows solid fundamentals with a P/E of 9.52, net income margin of 25.63%, and a history of beating earnings estimates in recent quarters. Recent news highlights operational recognition, including being named Arizona's #1 Best Bank by Forbes in June 2026 and announcing a $0.42 dividend for H1-2026.
The outlook is positive given strong profitability, consistent earnings beats, and overwhelming analyst support (79% Buy ratings). Key risks include significant negative operating cash flow in 2025 (-$2.68B) and reliance on financing activities for liquidity. The stock trades below the consensus price target of $90.67, offering potential upside if the company can improve cash generation from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
